UnitedHealth Group Inc (NYSE:UNH) will announce its first-quarter report before the open tomorrow, April 17. Ahead of the event, Wall Street anticipates earnings of $7.27 per share, a 5.2% increase from the same quarter a year ago, on revenue of $111.01 billion. UNH has been rallying since its late-February bear gap, hitting a nearly four-month high of $606.36 this past Friday. Year-to-date, the equity is up 16.8% despite broad-market pressures, and sits above all moving averages between the 20- and 320-day ...

Group 1: Market Overview - The market has experienced sharp volatility recently, but not all stocks have been negatively impacted, with UnitedHealth (UNH), Newmont (NEM), and Sprouts Farmers Market (SFM) showing positive gains [1][8]. Group 2: Newmont (NEM) - Newmont is one of the largest gold producers globally, with active mines in Nevada, Peru, Australia, and Ghana, benefiting from a surge in gold prices, resulting in a nearly 50% year-to-date performance increase [4]. - The average gold price per ounce reached $2,643, up from $2,004 in the same period last year, contributing to a record free cash flow of $1.6 billion [5]. - Analysts have raised their EPS expectations for Newmont, reflecting a bullish near-term outlook [7]. Group 3: UnitedHealth (UNH) - UnitedHealth provides a comprehensive range of health benefits, with its Optum segment leveraging data and technology to enhance care delivery and health outcomes [9]. - The company is expected to report a 5% year-over-year EPS growth on 11% higher sales, having exceeded EPS estimates in the last 20 quarterly releases [10][11]. - UnitedHealth's domestic operations provide a buffer against tariff concerns [11]. Group 4: Sprouts Farmers Market (SFM) - SFM has shown strong performance, exceeding consensus EPS and sales expectations for the last ten quarters, with a stock increase of nearly 160% over the past year [12]. - The company reported $2.0 billion in sales, reflecting a 17% year-over-year growth, indicating strong demand [14]. - SFM holds a Zacks Rank 1 (Strong Buy), with a notably bullish EPS outlook [15]. Group 5: Conclusion - Despite ongoing market volatility and tariff headlines, UnitedHealth, Newmont, and Sprouts Farmers Market have all demonstrated upward momentum and possess bullish near-term EPS outlooks [16].

Currently, CVS Health (CVS) and UnitedHealth Group (UNH) are two major vertically integrated behemoths in the U.S. healthcare market and key constituents of the S&P 500 index. Both companies have transformed beyond their original identities — CVS Health from a retail pharmacy chain into a healthcare powerhouse through its acquisition of Aetna and UnitedHealth from a traditional insurer into a tech-enabled care provider via its expansive Optum platform. Each now combines insurance, care delivery, pharmacy be ...

Key Takeaways Guidance will be key from both companies, a theme we'll see in the Q1 reporting cycle. Both stocks have showed great relative strength in 2025. Earnings season is always exciting for investors, with companies finally pulling the curtain back and unveiling what’s happened behind the scenes. Guidance is notably more critical this reporting cycle, given the recent tariff-induced spooks that we’ve become accustomed to.Importantly, several notable large-cap stocks are reporting this week, a list t ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even ...

Analysts on Wall Street project that UnitedHealth Group (UNH) will announce quarterly earnings of $7.27 per share in its forthcoming report, representing an increase of 5.2% year over year. Revenues are projected to reach $111.01 billion, increasing 11.2% from the same quarter last year.The current level reflects an upward revision of 0.1% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial pro ...

March 2025 might seem like ages ago in market years, as the Trump tariffs have rocked the market like few things before it. However, the trends in March are not so different from what's happening now, as consumer sentiment was rapidly weakening and fears of a recession were mounting before the tariff announcement.Let's take a look at the two best-performing Dow Jones Industrial Average (^DJI 1.26%) companies to see if they're worth buying today. 1. UnitedHealth Group (up 10.3% in March)UnitedHealth Group (U ...

UnitedHealth Group Incorporated (UNH) is set to report first-quarter 2025 results on April 17, 2025, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is currently pegged at $7.27 per shareon revenues of $111.01 billion. See the Zacks Earnings Calendar to stay ahead of market-making news.First-quarter earnings estimates have remained stable over the past week. The bottom-line projection indicates an increase of 5.2% from the year-ago reported number. The Zacks C ...

Investment Rating - The report assigns an investment rating of AAA to Johnson & Johnson, AA to Lilly, and AA to Roche, among others [95]. Core Insights - The pharmaceutical industry has seen a marginal increase of 1% in the collective brand value of the top 25 brands in 2025, with the US contributing significantly [20][21]. - Johnson & Johnson remains the most valuable pharmaceutical brand with a brand value of USD 15.5 billion, reflecting a 16% increase [27][34]. - Lilly has experienced the fastest growth in brand value, rising 36% to USD 8 billion, primarily due to its successful weight-loss drugs [40][41]. - The medical devices sector has grown by 5%, with Medtronic now leading the market with a brand value of USD 7.4 billion [23][57]. - The healthcare services sector is under pressure, with a collective decline of 11% in brand value among the top brands, except for UnitedHealthcare, which saw a 14% increase [24][65]. Sector Overview - The pharmaceutical sector is stable, with ongoing consolidation through mergers and acquisitions, such as Amgen's acquisition of Horizon Therapeutics [21]. - Innovation is crucial, with brands like Novo Nordisk and Lilly achieving significant brand value increases through breakthrough drugs [22]. - The medical devices industry is expanding, driven by advancements in technology and patient outcomes [23]. - The US healthcare services sector faces challenges, with declining public sentiment and scrutiny affecting brand reputations [24][25]. Valuation Analysis - Johnson & Johnson's brand value growth is supported by strong sales of key drugs and a commitment to innovation, with plans to invest over USD 55 billion in the US [36]. - Lilly's strategic acquisitions and successful product launches have bolstered its market position [41][43]. - Bayer's brand value increased by 13% to USD 6.2 billion, driven by improved consumer trust [29]. - Novo Nordisk's brand value rose by 7% to USD 5.5 billion, supported by its successful diabetes treatments [30]. Brand Strength Analysis - Johnson & Johnson leads with a Brand Strength Index (BSI) score of 83.5, reflecting strong brand equity [47]. - Bayer follows with a BSI of 82.2, benefiting from its consumer health products [52]. - Pfizer's BSI is 76.3, influenced by its role in the COVID-19 pandemic [54]. Medical Devices - Medtronic's brand value increased by 2% to USD 7.4 billion, driven by recovery in volume and new product introductions [57]. - Terumo experienced the highest growth in the sector, with a 52% increase in brand value to USD 2.3 billion [58]. - Philips leads in brand strength with a BSI of 87.8, benefiting from its consumer-facing electronics business [60]. Healthcare Services - UnitedHealthcare is the most valuable healthcare services brand, with a brand value of USD 54.2 billion and a BSI of 84.76 [65]. - The brand's growth is attributed to increased patient volumes in Medicare Advantage and Medicaid offerings [66]. - Other healthcare brands have seen significant declines, with Elevance Health and Aetna experiencing drops of 34% and 25%, respectively [70].

Group 1: Upcoming Earnings Reports - Major banks such as Goldman Sachs, Citigroup, and Bank of America are set to report earnings next week, with Goldman Sachs expected to perform well due to management confidence and downsizing efforts [1][2] - Citigroup's stock is anticipated to gain regardless of quarterly performance, while Bank of America is expected to post decent earnings based on recent trends [3] - Johnson & Johnson's earnings report will be closely watched for updates on ongoing litigation and potential news about new drugs, which could positively impact its stock [4] Group 2: Other Notable Earnings - Abbott Laboratories is expected to show strength in its franchises but may also address ongoing lawsuits affecting its stock [5] - Taiwan Semiconductor, UnitedHealth, and American Express will report earnings on Thursday, with UnitedHealth being labeled a "universal buy" and American Express expected to have a strong quarter despite potential post-report trading issues [7] - Netflix's earnings call is anticipated to highlight its ad-tier subscription model, although external factors such as political drama may overshadow its news [8] Group 3: Economic Indicators - Retail sales data will be released on Wednesday, with expectations of strong numbers based on positive signals from major retailers like Walmart, Amazon, and Costco [6]